Anchor Therapeutics

Anchor Therapeutics was a biotechnology company specializing in the development of pepducins, a proprietary class of cell-penetrating peptides. These molecules were designed to target G protein-coupled receptors (GPCRs) by interacting with the intracellular loops of the receptor, providing a unique mechanism for modulating signaling. The company's platform aimed to address "undruggable" GPCR targets involved in inflammation, oncology, and cardiovascular diseases. Anchor established significant collaborations, including a notable partnership with Ortho-McNeil-Janssen to develop treatments for metabolic and inflammatory disorders. Although the company successfully advanced its lead candidate, PZ-128, into clinical trials, it eventually ceased operations.